Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma

Jin,Yunfeng; Zou,Yi; Wan,Linling; Lu,Mingming; Liu,Ya; Huang,Guoqin; Wang,Jiandong; Xi,Qinghua

doi:10.3892/mmr.2018.8528

Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma

Authors:
- Yunfeng Jin
- Yi Zou
- Linling Wan
- Mingming Lu
- Ya Liu
- Guoqin Huang
- Jiandong Wang
- Qinghua Xi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Obstetrics and Gynecology, Affiliated Haian People's Hospital of Nantong University, Nantong, Jiangsu 226600, P.R. China, Department of Obstetrics and Gynecology, Affiliated Maternal and Child Health Care Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China, Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu 210002, P.R. China
Published online on: January 31, 2018 https://doi.org/10.3892/mmr.2018.8528
Pages: 5409-5415

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eph receptor‑A1 (EphA1) was the first member of the erythropoietin producing hepatocellular carcinoma (Eph) family of receptor tyrosine kinases. Although the roles of EphA1 in the tumorigenesis of various human cancers have been investigated, few studies have focused on ovarian carcinoma. The present study aimed to explore the profile of EphA1 expression in ovarian carcinomas, to analyzed the association between EphA1 expression and clinicopathologic parameters, and to investigate the roles of overexpressed EphA1 in ovarian cancer cells. EphA1 protein was detected in ovarian cancer cell lines and in a set of formalin‑fixed tissues, including normal fallopian tube, ovarian benign serous cystadenoma, borderline serous tumors and serous carcinoma. Ovarian cancer cell lines HO8910 and A2780 were transiently transfected with EphA1‑pCMV6‑GFP plasmid, and the proliferation and apoptosis of cells were measured. The association between EphA1 expression and clinicopathological parameters was statistically analyzed. EphA1 expression was negative in HO8910 and weakly positive in A2780 cells. The proliferation rate was significantly reduced in ovarian cancer cells after transfection with EphA1 plasmid compared with cells transfected with mock plasmid or untreated cells, but no obvious alteration in apoptosis was detected among these groups. EphA1 expression was positively detected in all normal fallopian tubes (10/10, 100%) and ovarian benign serous cystadenomas (12/12, 100%) as well as in some borderline serous tumors (9/15, 60%) and ovarian serous carcinomas (33/76, 43.42%). EphA1 expression was associated with grade of ovarian serous carcinomas, with loss of EphA1 more often observed in high‑grade tumors (P=0.016) and high Ki67 index tumors (P=0.007). These data suggest that EphA1 might be a useful marker for distinguishing low grade from high‑grade ovarian serous carcinoma.

View Figures

View References

1	Ciucci A, Zannoni GF, Buttarelli M, Martinelli E, Mascilini F, Petrillo M, Ferrandina G, Scambia G and Gallo D: Ovarian low and high grade serous carcinomas: Hidden divergent features in the tumor microenvironment. Oncotarget. 7:68033–68043. 2016. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Seebacher V, Reinthaller A, Koelbl H, Concin N, Nehoda R and Polterauer S: The impact of the duration of adjuvant chemotherapy on survival in patients with epithelial ovarian cancer-a retrospective study. PLoS One. 12:e01692722017. View Article : Google Scholar : PubMed/NCBI
4	Takekuma M, Wong KK and Coleman RL: A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib. Gynecol Oncol Res Pract. 3:52016. View Article : Google Scholar : PubMed/NCBI
5	Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell. 90:403–404. 1997. View Article : Google Scholar : PubMed/NCBI
6	Pasquale EB: Eph receptors and ephrins in cancer: Bidirectional signalling and beyond. Nat Rev Cancer. 10:165–180. 2010. View Article : Google Scholar : PubMed/NCBI
7	Drescher U: The Eph family in the patterning of neural development. Curr Biol. 7:R799–R807. 1997. View Article : Google Scholar : PubMed/NCBI
8	Mellitzer G, Xu Q and Wilkinson DG: Eph receptors and ephrins restrict cell intermingling and communication. Nature. 400:77–81. 1999. View Article : Google Scholar : PubMed/NCBI
9	Xu Q, Mellitzer G, Robinson V and Wilkinson DG: In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature. 399:267–271. 1999. View Article : Google Scholar : PubMed/NCBI
10	Holmberg J, Clarke DL and Frisén J: Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature. 408:203–206. 2000. View Article : Google Scholar : PubMed/NCBI
11	Cooke J, Moens C, Roth L, Durbin L, Shiomi K, Brennan C, Kimmel C, Wilson S and Holder N: Eph signalling functions downstream of Val to regulate cell sorting and boundary formation in the caudal hindbrain. Development. 128:571–580. 2001.PubMed/NCBI
12	Herath NI and Boyd AW: The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer. 126:2003–2011. 2010.PubMed/NCBI
13	Takano H, Nakamura T, Tsuchikawa T, Kushibiki T, Hontani K, Inoko K, Takahashi M, Sato S, Abe H, Takeuchi S, et al: Inhibition of Eph receptor A4 by 2,5-dimethylpyrrolyl benzoic acid suppresses human pancreatic cancer growing orthotopically in nude mice. Oncotarget. 6:41063–41076. 2015. View Article : Google Scholar : PubMed/NCBI
14	Husa AM, Magić Ž, Larsson M, Fornander T and Pérez-Tenorio G: EPH/ephrin profile and EPHB2 expression predicts patient survival in breast cancer. Oncotarget. 7:21362–21380. 2016. View Article : Google Scholar : PubMed/NCBI
15	Mateo-Lozano S, Bazzocco S, Rodrigues P, Mazzolini R, Andretta E, Dopeso H, Fernández Y, Del Llano E, Bilic J, Suárez-López L, et al: Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Sci Rep. 7:437022017. View Article : Google Scholar : PubMed/NCBI
16	Hirai H, Maru Y, Hagiwara K, Nishida J and Takaku F: A novel putative tyrosine kinase receptor encoded by the eph gene. Science. 238:1717–1720. 1987. View Article : Google Scholar : PubMed/NCBI
17	Duffy SL, Steiner KA, Tam PP and Boyd AW: Expression analysis of the Epha1 receptor tyrosine kinase and its high-affinity ligands Efna1 and Efna3 during early mouse development. Gene Expr Patterns. 6:719–723. 2006. View Article : Google Scholar : PubMed/NCBI
18	Yamazaki T, Masuda J, Omori T, Usui R, Akiyama H and Maru Y: EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 122:243–255. 2009. View Article : Google Scholar : PubMed/NCBI
19	Hafner C, Becker B, Landthaler M and Vogt T: Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol. 19:1369–1377. 2006. View Article : Google Scholar : PubMed/NCBI
20	Dong Y, Wang J, Sheng Z, Li G, Ma H, Wang X, Zhang R, Lu G, Hu Q, Sugimura H and Zhou X: Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol. 22:151–160. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang J, Dong Y, Wang X, Ma H, Sheng Z, Li G, Lu G, Sugimura H and Zhou X: Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep. 24:1577–1584. 2010.PubMed/NCBI
22	Wang X, Liu Y, Cao G, Zhang X, Xu H, Xu H and Wang J: Expression of the EphA1 protein is associated with Fuhrman nuclear grade in clear cell renal cell carcinomas. Int J Clin Exp Pathol. 8:6821–6827. 2015.PubMed/NCBI
23	Kurman RJ, Carcangiu ML, Herrington CS and Young RH: WOH Classification of Tumours of Female Reproductive Organs. International Agency for Research on Cancer; Lyon: 2014
24	Miyazaki K, Inokuchi M, Takagi Y, Kato K, Kojima K and Sugihara K: EphA4 is a prognostic factor in gastric cancer. BMC Clin Pathol. 13:192013. View Article : Google Scholar : PubMed/NCBI
25	Fox BP and Kandpal RP: Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun. 318:882–892. 2004. View Article : Google Scholar : PubMed/NCBI
26	Nakagawa M, Inokuchi M, Takagi Y, Kato K, Sugita H, Otsuki S, Kojima K, Uetake H and Sugihara K: Erythropoietin-producing hepatocellular A1 is an independent prognostic factor for gastric cancer. Ann Surg Oncol. 22:2329–2335. 2015. View Article : Google Scholar : PubMed/NCBI
27	Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E and Theocharis S: Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: Associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Clin Pathol. 14:82014. View Article : Google Scholar : PubMed/NCBI
28	Fox BP, Tabone CJ and Kandpal RP: Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun. 342:1263–1272. 2006. View Article : Google Scholar : PubMed/NCBI
29	Wang J, Ma J, Dong Y, Shen Z, Ma H, Wang X, Shi S, Wu J, Lu G, Peng L and Zhoud X: High expression of EphA1 in esophageal squamous cell carcinoma is associated with lymph node metastasis and advanced disease. APMIS. 121:30–37. 2013. View Article : Google Scholar : PubMed/NCBI
30	Peng L, Wang H, Dong Y, Ma J, Wen J, Wu J, Wang X, Zhou X and Wang J: Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score. Int J Clin Exp Pathol. 6:1854–1860. 2013.PubMed/NCBI
31	Wong YL, Dali AZ, Mohamed Rose I, Jamal R and Mokhtar NM: Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling. Asia Pac J Clin Oncol. 12:e259–e268. 2016. View Article : Google Scholar : PubMed/NCBI
32	Herath NI, Spanevello MD, Sabesan S, Newton T, Cummings M, Duffy S, Lincoln D, Boyle G, Parsons PG and Boyd AW: Over-expression of Eph and ephrin genes in advanced ovarian cancer: Ephrin gene expression correlates with shortened survival. BMC cancer. 6:1442006. View Article : Google Scholar : PubMed/NCBI
33	Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, et al: Aurora kinase a expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J Ovarian Res. 9:312016. View Article : Google Scholar : PubMed/NCBI
34	Gu Y, Li F, Qian N, Chen X, Wang H and Wang J: Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. J Clin Pathol. 69:448–453. 2016. View Article : Google Scholar : PubMed/NCBI